Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Ivan, Vyshnyvetskyy"'
Autor:
Mark H. Moss, Njira L. Lugogo, Mario Castro, Nicola A. Hanania, Andrea Ludwig-Sengpiel, Dinesh Saralaya, Rafal Dobek, Iñigo Ojanguren, Ivan Vyshnyvetskyy, Jean-Marie Bruey, Robin Osterhout, Cindy-ann Tompkins, Karen Dittrich, Kartik Raghupathi, Hector Ortega
Publikováno v:
Scientia
Asthma; Asthma worsening; Eosinophilic asthma Asma; Empitjorament de l'asma; Asma eosinofílica Asma; Empeoramiento del asma; Asma eosinofílica Background Prostaglandin D2 receptor 2 (DP2) antagonists inhibit prostaglandin D2-induced effects, includ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7cb6aa1f9e35d8b8f1d34f6669cbfc1
https://doi.org/10.1016/j.chest.2022.02.038
https://doi.org/10.1016/j.chest.2022.02.038
Autor:
Igor, Kaidashev, Anna, Lavrenko, Tatiana, Baranovskaya, Victor, Blazhko, Nataliia, Digtiar, Oleksandr, Dziublyk, Nataliia, Gerasymenko, Liudmyla, Iashyna, Volodymyr, Kryvetskyi, Lesya, Kuryk, Victoria, Rodionova, Roman, Stets, Ivan, Vyshnyvetskyy, Yurii, Feshchenko
Publikováno v:
Acta bio-medica : Atenei Parmensis. 93(2)
Empiric therapy of community-acquired pneumonia (CAP) remains the standard care and guidelines are mostly based on published data from the United States or Europe. In this study, we determined the bacterial etiology of CAP and evaluated the clinical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4aae29786344e1d3074bc2c497c263a3
https://pubmed.ncbi.nlm.nih.gov/35545995
https://pubmed.ncbi.nlm.nih.gov/35545995
Autor:
Mark H, Moss, Njira L, Lugogo, Mario, Castro, Nicola A, Hanania, Andrea, Ludwig-Sengpiel, Dinesh, Saralaya, Rafal, Dobek, Iñigo, Ojanguren, Ivan, Vyshnyvetskyy, Jean-Marie, Bruey, Robin, Osterhout, Cindy-Ann, Tompkins, Karen, Dittrich, Kartik, Raghupathi, Hector, Ortega
Publikováno v:
Chest. 162(2)
Prostaglandin DWhat is the effect of the DPIn this phase IIb, randomized, double-blind, placebo-controlled, dose-ranging, parallel-group, multicenter study, GB001 or placebo was added to standard-of-care treatment in patients with moderate to severe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::08a30a457306a46e34ea0b7ad0895bf2
https://pubmed.ncbi.nlm.nih.gov/35248549
https://pubmed.ncbi.nlm.nih.gov/35248549
Publikováno v:
EUREKA: Health Sciences. 3:3-9
The resulting criterion of assessment of staff management effectiveness in health protection institution is a satisfaction of medical workers with their work. So, it is important to know the predictors of satisfaction and dissatisfaction with the wor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f531553973708766063dc001b42886ae
https://doi.org/10.21303/2504-5679.2017.00332
https://doi.org/10.21303/2504-5679.2017.00332
Autor:
Abdulbaki Kumbasar, Pieter Gillard, Miguel Urina, Oner Ozdogan, Jonathan Barratt, Erik Penne, Ru San Tan, Carlos Eduardo Poli de Figueiredo, Bertrand Cariou, Trine Elisabeth Finnes, Sofia Malyutina, Andreas Kistler, Ciprian Constantin, Ruslan Sardinov, Dominique Guerrot, Goos Laverman, Jingmei Li, Alessia Fornoni, Konstantin Nikolaev, Gunnar Gislason, Asad Bhorat, Idalina Beirão, Markus Van der Giet, Nataliia Pashkovska, Ilona Kurnatowska, Ivan Vyshnyvetskyy, Mario Cozzolino, Maria Isabel Troya
Publikováno v:
ABACUS. Repositorio de Producción Científica
Universidad Europea (UEM)
Bakris, George L; Agarwal, Rajiv; Anker, Stefan D; Pitt, Bertram; Ruilope, Luis M; Nowack, Christina; Kolkhof, Peter; Ferreira, Anna C; Schloemer, Patrick; Filippatos, Gerasimos (2019). Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial. American journal of nephrology, 50(5), pp. 333-344. Karger 10.1159/000503713
Universidad Europea (UEM)
Bakris, George L; Agarwal, Rajiv; Anker, Stefan D; Pitt, Bertram; Ruilope, Luis M; Nowack, Christina; Kolkhof, Peter; Ferreira, Anna C; Schloemer, Patrick; Filippatos, Gerasimos (2019). Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial. American journal of nephrology, 50(5), pp. 333-344. Karger 10.1159/000503713
Background: Among diabetics, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality, and progression of their underlying disease. Finerenone is a novel, non-steroidal, selective mineralocorticoid-recept
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e0b00b79939a833dc491c37063eb15b
http://hdl.handle.net/11268/8561
http://hdl.handle.net/11268/8561
Publikováno v:
Chest. 142:418A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bca2f484e7d2810c7c32067c4da67cef
https://doi.org/10.1378/chest.1388728
https://doi.org/10.1378/chest.1388728